Background {#Sec1}
==========

Patients requiring intensive care unit (ICU) admission are at increased risk of death, owning to a variety of life-threatening conditions such as respiratory failure, shock, severe infection and multiple organ dysfunction \[[@CR1], [@CR2]\]. Metabolic response to critical illness is characterized by accelerated catabolism, resulting in wasting and negative nitrogen balance \[[@CR3]\]. Nutritional support during the catabolic phase will not only lead to positive nitrogen balance but also prevent weakness and, eventually, multiple organ failure and death \[[@CR4], [@CR5]\]. Regarding the route of energy administration, enteral feeding has been proven to be superior to the parenteral nutrition in terms of the outcomes such as nosocomial infection, medical cost saving and even mortality rate \[[@CR6]--[@CR9]\]. Thus, enteral nutrition (EN) feeding is the primary choice of nutrition therapy in current clinical practice; a careful and well-monitored approach is proposed based on the risk of poor tolerance \[[@CR10]\]. Critically ill patients usually have compromised gastrointestinal function, making it difficult to increase EN to a target. Other factors that can delay achieving a target EN proportion include compromised gastric function, abdominal surgery and unstable hemodynamics \[[@CR11]\]. The clinical practices of EN feeding vary substantially across different regions and hospitals.

China has the world's largest population of critically ill patients, and the clinical practice of EN feeding varies substantially across regions and hospitals. However, to the best of our knowledge, there is a lack of large-scale data on the practice of enteral nutrition in ICUs. Previous small studies have shown that the proportion of EN was as low as 40% on day 2, which could probably be improved with implementation of an EN feeding protocol \[[@CR12], [@CR13]\]. Compliance to the clinical practice guidelines was also found to be suboptimal in neurological ICUs \[[@CR14]\]. Due to the lack of epidemiological data on clinical practice of EN in Chinese ICUs, a nationwide cross-sectional study was performed. The objective of the study was to provide epidemiological data on the clinical practice of EN feeding in Chinese ICUs. Also, factors associated with the initiation and proportion of EN were investigated. We hypothesized that the severity of illness and gastrointestinal function would influence the timing and quantity of EN feeding.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This cross-sectional study was conducted in 118 ICUs of 116 hospitals covering most provinces of mainland China on April 26, 2017. The types of ICUs in this study vary, including general ICUs, surgical ICUs, medical ICUs, respiratory ICUs, coronary ICUs, emergency ICUs and so on. Demographic and clinical variables of patients on April 25, 2017 (hereafter referred to as "the study day") were recorded. The outcome of the study subjects on the 28th day after investigation was obtained. Data collection was performed via a customized website. The study was approved by the ethics committee of Jinling Hospital (approval no. 2017NZKY-010-01).

Study population {#Sec4}
----------------

At 00:00 on April 26, 2017, all patients in the study ICUs were included. Exclusion criteria were: patients or their surrogate refused to participate in the study; and patients whose 28-day outcomes were not recorded.

Variables {#Sec5}
---------

Demographics such as age, gender, source of admission, weight (past weight and temporal weight) and height were obtained. The past weight was defined as the body weight when patients were healthy or before 1 week, whereas the temporal weight was the body weight on the study day or within 1 week. The dates of hospital admission and ICU admission were reviewed.

Routine laboratory tests of blood samples were measured, for example, C-reactive protein (CRP), percentage of lymphocyte, albumin, maximum and minimum blood glucose, and arterial lactate. The level of consciousness was estimated using the Glasgow Coma Scale (GCS). If a patient was under sedation, the sedative was reduced or discontinued to make an appropriate assessment. Vital signs such as mean blood pressure and some particular treatments such as using vasopressors were recorded for Sequential Organ Failure Assessment (SOFA) and Acute Physiologic and Chronic Health Evaluation II (APACHE II) scores. The maximum and minimum blood glucose (BG) values on the study day were also reported. If a patient had more than one measurement of these variables on the study day, the worst one was chosen.

The date for the start of EN was retrospectively recorded in the study, but details regarding EN delivery were only recorded on the study day. Gastrointestinal function was evaluated as normal or mild injured, moderate to severe injured and failure referring to the acute gastrointestinal injury (AGI) grading. Enteral feeding volume and energy density of EN were recorded in the units of milliliters and kilocalories per milliliter, respectively. The EN proportion of target was computed as the ratio of the energy provided by EN to the estimated energy target (= past body weight × 25 kcal/kg). The nutrition could be warmed and diluted, and the dilution effect was considered in calculating the targets--achievement ratio. The enteral feeding routes included gastric feeding, postpyloric feeding, percutaneous gastrostomy/jejunostomy (PEG/J), jejunostomy and others \[[@CR15]\]. The EN administration styles included continuous pump, gravity, intermittent feeding and other styles. The body positions were recorded as elevation of the bed head by 30°, sitting or other positions. The frequency of gastric residual volume (GRV) measurement and the largest GRV were recorded. In a case when gastrointestinal decompression was used, GRV was not measured and the gastrointestinal decompression volume was measured. Abdominal pressure was estimated using the bladder pressure. Duration of EN feeding was defined as the hours of the study day during which EN was administered. The times and causes of EN discontinuation during the study day were recorded. Intolerance to EN included nausea, vomiting, aspiration, abdominal pain and distension, and diarrhea. The presence of nausea and vomiting were recorded as yes, no, unable to judge and so on. The severity of abdominal pain and distension were grade-evaluated. Stool frequency and total volume on the study day were recorded.

The outcome status at 28 days after the study day was recorded as the endpoint. The outcome variable was labeled as alive, dead and lost, corresponding to vital status of a subject. If a patient's condition on day 28 was not available, he/she was considered lost to follow-up.

Patients with missing outcomes {#Sec6}
------------------------------

Missing values were present in the dataset. We performed single imputation for missing values \[[@CR16]\]. For patients with missing values on outcome, their baseline characteristics were also reported and compared with those with a complete dataset.

Statistical analysis {#Sec7}
--------------------

Continuous variables were expressed as mean and standard error, or median and interquartile range, as appropriate. Categorical data were expressed as the number and proportion. Because there were two groups in the study, analysis of variance was performed for normally distributed data and the Kruskal--Wallis test was used for nonnormal data. Categorical data were compared using the chi-square test \[[@CR16], [@CR17]\].

The initiation of EN was considered as survival data and a multivariable Cox proportional hazard regression model was performed to investigate factors associated with the initiation of EN \[[@CR17]\]. Variables included in the model were the source of admission, age, SOFA and APACHE II scores, gender, AGI grading and GCS score. The selection of variables was based on the literature finding that severity of illness was associated with EN delivery, and demographics of age and gender were also included.

The factors associated with the proportion of EN on the study day were investigated in a multivariable linear regression model \[[@CR18]\]. Variables were selected using a stepwise backward elimination method and the best model was judged by the Akaike information criterion (AIC) \[[@CR19]\]. The final model included variables such as the source of admission, age, APACHE II score, SOFA score, gender, AGI grading and GCS score. The cross-sectional study was subject to length bias, in which patients who had a longer length of stay in the ICU were more likely to be included in the study. Thus, the patients included in the study were not an unbiased sample of the target population. To adjust for this length bias, we assigned higher weights to patients with shorter LOS in the ICU \[[@CR20]\].

All statistical analyses were performed using R (version 3.3.2) \[[@CR21]\]. Two-tailed *p* \< 0.05 was considered to indicate statistical significance.

Results {#Sec8}
=======

Characteristics of enrolled patients {#Sec9}
------------------------------------

The baseline characteristics and variables for the study day are presented in Table [1](#Tab1){ref-type="table"}. A total of 1953 patients were included for analysis, including 1483 survivors and 312 nonsurvivors. The median study day was day 7 (IQR 2--19 days) after ICU entry, and there was no difference between survivors and nonsurvivors. Nonsurvivors were significantly older than survivors (median 70 vs 66 years; *p* = 0.005 for two-group comparison). There were more males among both survivors (68%) and nonsurvivors (63%). Most of the study patients came from emergency departments (35%), followed by surgery (29%) and internal medicine (19%). The distribution of admission wards was similar for survivors and nonsurvivors. Past and temporal weight (median 65 vs 65 kg, 65 vs 63 kg; *p* = 0.369, 0.198 for two-group comparison) and EN start day (median 1 (0, 2.5) vs 1 (0, 2) days; *p* = 0.912 for two-group comparison) showed no difference between the two groups.Table 1Cross-sectional characteristics between groupsVariableTotal (*n* = 1953)Survivors (*n* = 1483)Nonsurvivors (*n* = 312)Lost to follow up (*n* = 158)*p* value Study day with reference to ICU entry7 (2, 19)7 (2, 19)6 (2, 15.5)7 (3, 20)0.131 Age67 (51, 80)66 (51, 80)70 (57.75, 81)69.5 (51, 81)0.008 Sex (male, %)1315 (0.67)1011 (0.68)197 (0.63)107 (0.68)0.216Source of admission Emergency room664 (0.35)509 (0.35)95 (0.32)60 (0.39)0.008 Surgery545 (0.29)430 (0.3)73 (0.24)42 (0.27)0.008 Internal medicine362 (0.19)255 (0.18)81 (0.27)26 (0.17)0.008 Other ward126 (0.07)96 (0.07)16 (0.05)14 (0.09)0.008 Other hospital202 (0.11)155 (0.11)36 (0.12)11 (0.07)0.008 Past weight65 (60, 75)65 (59.45, 75)65 (58, 74)67 (60, 75)0.443 Temporal weight65 (55, 70)65 (55, 70)63 (54.2, 70)65 (60, 70)0.263 Height170 (160, 175)170 (160, 175)167 (160, 173)170 (160, 175)0.034 CRP (mmol/l)44.6 (16.8, 95.95)40.05 (15.5, 87)74.1 (29.85, 139.75)43.75 (14.3, 98.53)0 Lymphocyte (%)10.7 (6.3, 17.6)11.1 (6.8, 18.4)8 (5.07, 13.85)10.1 (6.3, 16.7)0 Albumin (mg/dl)31.7 (27.8, 35.3)32 (28.1, 35.6)30 (26.2, 34.2)32 (28.55, 35.35)0 Maximum BG (mmol/l)10.1 (8, 13.1)10 (7.9, 12.9)11.1 (8.75, 14.85)11.3 (8.3, 13.8)0 Minimum BG (mmol/l)6.4 (5.4, 7.8)6.3 (5.4, 7.6)6.8 (5.6, 8)6.05 (5.2, 7.9)0.054 Lactate (mmol/l)1.4 (1, 2)1.3 (0.9, 1.9)1.7 (1.2, 2.58)1.4 (0.95, 1.85)0 P/F ratio260 (182, 348)268 (196, 350)227 (135, 320)251 (160.5330)0 Platelet (× 10^9^/l)176 (115, 250)184 (124, 260)146 (82.25, 206.25)173 (108.75, 257)0 Total bilirubin (mmol/l)12 (7, 19)12 (7, 18)14 (8, 23)11 (8, 18.5)0.001 Mean blood pressure (mmHg)82 (72, 94)83 (73, 94)80 (70, 93)81 (70.5, 94.5)0.104 GCS score12 (7, 15)13 (7.75, 15)9 (5, 15)11 (6, 15)0 Serum creatinine (mmol/l)67 (48, 102.5)64 (47, 94)84 (55, 150)79.5 (55, 181.25)0 Urine output (ml/24 h)1800 (1100, 2468)1850 (1200, 2500)1500 (770, 2322.5)1800 (1007.5, 2400)0 SOFA score5 (3, 7)5 (3, 7)7 (5, 10)6 (4, 8)0 Body temperature (°C)37 (36.7, 37.7)37 (36.6, 37.6)37.2 (36.7, 38)37 (36.7, 37.52)0.002 Heart rate (/min)90 (80, 107)90 (79, 105)98 (85, 120)91 (80, 105)0 Respiratory rate (/min)20 (17, 24)20 (16, 24)20 (18, 26)20 (16, 23)0.003 White blood cell (× 10^9^/l)10 (7.2, 13.7)9.8 (7.1, 13)11 (7.75, 15.3)10.2 (7.5, 14.55)0.001 APACHE II score17 (12, 22)16 (11, 21)20 (15, 26)19 (13, 23)0 EN start day1 (0, 3)1 (0, 2.5)1 (0, 2)1 (0, 3.75)0.099 EN in prior 24 h1270 (0.66)966 (0.67)206 (0.66)98 (0.65)0.951 AGI 11440 (0.86)1141 (0.88)214 (0.78)85 (0.79)0 AGI 2--3210 (0.12)142 (0.11)51 (0.18)17 (0.16)0 AGI 433 (0.02)16 (0.01)11 (0.04)6 (0.06)0 Total volume of EN (ml)1000 (800, 1250)1000 (830, 1300)1000 (600, 1080)1000 (1000, 1225)0.203 Energy density of EN (kcal/ml)1 (1, 1.5)1 (1, 1.5)1 (1, 1.3)1 (1, 1.5)0.112 EN warming53 (0.04)37 (0.04)11 (0.06)5 (0.06)0.426 EN dilution538 (0.47)414 (0.48)87 (0.46)37 (0.47)0.944EN route Gastric1040 (0.85)783 (0.84)177 (0.88)80 (0.91)0.662 Jejunostomy10 (0.01)9 (0.01)1 (0)0 (0)0.662 PEG/J20 (0.02)19 (0.02)1 (0)0 (0)0.662 Postpyloric127 (0.1)101 (0.11)19 (0.1)7 (0.08)0.662 Other23 (0.02)20 (0.02)2 (0.01)1 (0.01)0.662EN delivery method Continuous pump1073 (0.88)821 (0.89)178 (0.88)74 (0.85)0.368 By gravity35 (0.03)27 (0.03)6 (0.03)2 (0.02)0.368 Intermittent86 (0.07)59 (0.06)17 (0.08)10 (0.11)0.368 Other22 (0.02)20 (0.02)1 (0)1 (0.01)0.368Position Bed head ≥30°1004 (0.83)771 (0.83)164 (0.82)69 (0.79)0.899 Bed head \<  30°194 (0.16)143 (0.15)34 (0.17)17 (0.2)0.899 Sitting11 (0.01)9 (0.01)1 (0)1 (0.01)0.899 Other7 (0.01)6 (0.01)1 (0)0 (0)0.899 Frequency of GRV measurement2 (0, 4)3 (0, 4)2 (0, 4)3 (0, 6)0.353 Maximum GRV (ml)0 (0, 50)0 (0, 50)10 (0, 52.5)10 (0, 50)0.517 Use of gastrointestinal decompression334 (0.17)229 (0.16)76 (0.25)29 (0.18)0.001 Gastrointestinal decompression (ml)100 (40, 250)100 (40, 200)100 (50, 300)100 (30, 300)0.854 Abdominal pressure (mmHg)11.36 (8.27, 14.19)11.03 (8.82, 14)12.5 (9.43, 15.33)7.35 (5.88, 10)0.083 Duration of EN delivery (hours)20 (15, 24)20 (14, 24)21 (12, 24)24 (20, 24)0.001EN discontinuation due to intolerance (times) 0997 (0.95)775 (0.95)161 (0.93)61 (0.94)0.318 131 (0.03)21 (0.03)6 (0.03)4 (0.06)0.318 220 (0.02)15 (0.02)5 (0.03)0 (0)0.318 32 (0)1 (0)1 (0.01)0 (0)0.318 42 (0)1 (0)1 (0.01)0 (0)0.318 51 (0)1 (0)0 (0)0 (0)0.318EN discontinuation due to examination (times) 0950 (0.9)732 (0.9)156 (0.91)62 (0.95)0.13 184 (0.08)68 (0.08)14 (0.08)2 (0.03)0.13 211 (0.01)11 (0.01)0 (0)0 (0)0.13 31 (0)0 (0)0 (0)1 (0.02)0.13 41 (0)1 (0)0 (0)0 (0)0.13 52 (0)1 (0)1 (0.01)0 (0)0.13 62 (0)1 (0)1 (0.01)0 (0)0.13EN discontinuation due to other reasons (times) 0983 (0.95)753 (0.94)166 (0.96)64 (0.98)0.99 132 (0.03)27 (0.03)4 (0.02)1 (0.02)0.99 28 (0.01)7 (0.01)1 (0.01)0 (0)0.99 34 (0)3 (0)1 (0.01)0 (0)0.99 56 (0.01)5 (0.01)1 (0.01)0 (0)0.99 63 (0)3 (0)0 (0)0 (0)0.99Presence of nausea No1670 (0.86)1303 (0.88)260 (0.84)107 (0.69)0.000 Unable to judge176 (0.09)107 (0.07)32 (0.1)37 (0.24)0.000 Yes93 (0.05)63 (0.04)18 (0.06)12 (0.08)0.000Presence of vomiting No1743 (0.9)1338 (0.91)272 (0.87)133 (0.85)0.108 Suspected65 (0.03)44 (0.03)12 (0.04)9 (0.06)0.108 Unable to judge29 (0.01)21 (0.01)5 (0.02)3 (0.02)0.108 Yes105 (0.05)70 (0.05)23 (0.07)12 (0.08)0.108Presence of aspiration No1809 (0.94)1378 (0.94)296 (0.95)135 (0.87)0.008 Suspected87 (0.05)59 (0.04)11 (0.04)17 (0.11)0.008 Unable to judge20 (0.01)17 (0.01)1 (0)2 (0.01)0.008 Yes17 (0.01)12 (0.01)4 (0.01)1 (0.01)0.008Presence of abdominal pain No1436 (0.74)1133 (0.77)214 (0.69)89 (0.57)0 Persistent77 (0.04)51 (0.03)18 (0.06)8 (0.05)0 Self resolution93 (0.05)66 (0.04)15 (0.05)12 (0.08)0 Unable to judge329 (0.17)218 (0.15)63 (0.2)48 (0.31)0Presence of abdominal distension Mild420 (0.22)311 (0.21)66 (0.21)43 (0.27)0.000 No1347 (0.69)1055 (0.71)199 (0.64)93 (0.59)0.000 Obvious100 (0.05)60 (0.04)28 (0.09)12 (0.08)0.000 Severe18 (0.01)11 (0.01)6 (0.02)1 (0.01)0.000 Unable to judge62 (0.03)40 (0.03)13 (0.04)9 (0.06)0.000Bowel sound Hyper37 (0.02)27 (0.02)7 (0.02)3 (0.02)0 Hypo443 (0.23)295 (0.2)103 (0.33)45 (0.29)0 None125 (0.06)90 (0.06)22 (0.07)13 (0.08)0 Normal1321 (0.69)1047 (0.72)179 (0.58)95 (0.61)0Stool Yes1103 (0.58)840 (0.59)175 (0.57)88 (0.57)0.469 No579 (0.31)436 (0.31)98 (0.32)45 (0.29)0.469 No within 3 days171 (0.09)119 (0.08)33 (0.11)19 (0.12)0.469 Colostomy23 (0.01)19 (0.01)1 (0)3 (0.02)0.469 Incontinence16 (0.01)14 (0.01)2 (0.01)0 (0)0.469 Stool frequency1 (1, 2)1 (1, 2)1 (1, 2)2 (1, 2)0.943 Stool volume (ml)200 (100, 350)200 (100, 350)200 (100, 300)200 (100, 350)0.266Stool description Granular hard18 (0.02)15 (0.02)2 (0.01)1 (0.01)0.946 Loose528 (0.52)400 (0.52)92 (0.56)36 (0.52)0.946 Shaped2 (0)2 (0)0 (0)0 (0)0.946 Shaped soft412 (0.41)323 (0.42)61 (0.37)28 (0.41)0.946 Soft5 (0)4 (0.01)1 (0.01)0 (0)0.946 Watery45 (0.04)32 (0.04)9 (0.05)4 (0.06)0.946Stool blood Black stool16 (0.02)9 (0.01)7 (0.04)0 (0)0.174 Bloody stool5 (0)4 (0.01)1 (0.01)0 (0)0.174 No946 (0.94)731 (0.95)148 (0.91)67 (0.96)0.174 OB positive38 (0.04)28 (0.04)7 (0.04)3 (0.04)0.174Statistics expressed as number of patients (proportion) or median (first and third interquartile range)*AGI* acute gastrointestinal injury, *BG* blood glucose, *APACHE II* Acute Physiology and Chronic Health Evaluation II, *CRP* C-reactive protein, *EN* enteral nutrition, *GCS* Glasgow Coma Score, *GRV* gastric residual volume, *ICU* intensive care unit, *PEG/J* percutaneous endoscopic gastrostomy/jejunostomy, *SOFA* Sequential Organ Failure Assessment, P/F parital pressure of oxygen/Fraction of inspired oxygen

For laboratory variables, CRP (median 40.1 vs 74.1 mg/dl; *p* \< 0.001), maximum BG (median 10 vs 11.1 mmol/l; *p* \< 0.001), minimum BG (median 6.3 vs 6.8 mmol/l; *p* \< 0.001), lactate (median 1.3 vs 1.7 mmol/l; *p* \< 0.001) and total bilirubin (median 12 vs 14 mmol/l; *p* \< 0.001) were significantly lower in survivors than those in nonsurvivors, while the GCS was significantly higher (median 13 vs 9; *p* \< 0.001). As expected, the SOFA score (median 7 vs 5; *p* \< 0.001) and APACHE II score (median 20 vs 16; *p* \< 0.001) were higher in the nonsurvivors than that in the survivors.

EN delivery {#Sec10}
-----------

There were 1440 patients in AGI 1 (86%), 210 patients in AGI 2--3 (12%) and 33 patients in AGI 4 (2%). The severity of AGI was associated with mortality, as there were significantly more patients with AGI 1 in the survivors (88% vs 78%; *p* \< 0.001) than in the nonsurvivors, and more patients had AGI 2--3 (18% vs 11%; *p* = 0.001) and AGI 4 (4% vs 1%) in the nonsurvivors than in the survivors.

There were 1270 patients using EN (66%) on the study day and there was no difference between survivors and nonsurvivors (67% vs 66%). The mean total volume of EN was 1000 ml in the two groups. The energy density of EN was 1 or 1.5 kcal/ml for different formulas. However, the proportion of starting EN within 24, 48 and 72 h after ICU entry was 23.9% (84/352), 32.7% (150/459) and 37.0% (200/541), respectively. The proportion of subjects receiving \> 80% estimated energy target within 24, 48, 72 h and 7 days after ICU entry was 10.5% (37/352), 10.9% (50/459), 11.8% (64/541) and 17.8% (162/910), respectively. Data on the proportion of EN were only available for the study day. Thus, the calculation of EN proportion within 24, 48, 72 and 7 days only included patients for whom the study days were within the relevant time window (a subset of all patients) and not from all recruited patients. Figure [1](#Fig1){ref-type="fig"} plots the number of patients with different EN proportions against the study days (e.g., with reference to the day of ICU entry), showing that the use of EN increased over time.Fig. 1Number of patients with different EN proportions stratified by different study days. Nearly two thirds of patients did not use EN within 2 days after ICU entry. Both the proportion of patients using EN and EN proportions of total energy target increased over time, but less than half of patients received \> 60% total target after first week in ICU. d days, EN enteral nutrition, ICU intensive care unit

Gastric feeding was used in 85% patients, followed by postpyloric feeding (11%), PEG/J (2%) and jejunostomy (2%). Continuous pump (88%) was the predominant EN infusion style, followed by intermittent pump (7%) and infusion by gravity (3%). The majority of patients (83%) had their bed head elevated more than 30°. Warming was used in 47% of patients and EN was not diluted for the majority of cases (96%). The frequency and the total volume of GRV measurement were 2 (IQR 0--4) times and 0 (IQR 0--50) ml. The gastrointestinal depression volume and abdominal pressure were 100 (IQR 40--250) ml and about 14 (IQR 11--18) mmHg. EN was not discontinued for the majority of patients in the study day; the reasons for EN discontinuation were intolerance (52 patients, 5%), examination (98 patients, 9%) and others (52 patients, 5%). However, none of these EN-related parameters was significantly associated with mortality outcome, except for the proportion of gastrointestinal decompression (16% vs 25%; *p* \< 0.001).

Factors associated with EN initiation {#Sec11}
-------------------------------------

In the Cox proportional hazard model (Table [2](#Tab2){ref-type="table"}), we found that the AGI and GCS were associated with initiation of EN. Using AGI 1 as the reference, patients with AGI 2--3 were associated with reduced likelihood of EN initiation (HR 0.46, 95% CI 0.353--0.599; *p* \< 0.001). AGI 4 was significantly associated with lower hazard of EN administration (HR 0.056, 95% CI 0.008--0.398; *p* = 0.004). Although a greater value of GCS was statistically associated with reduced likelihood of EN initiation, the clinical significance was marginal (HR 0.945, 95% CI 0.921--0.969; *p* \< 0.001).Table 2Variables associated with enteral nutrition initiationHR2.5%97.5%*p* valueSource of admission (emergency room as reference)Surgery1.0870.8781.3460.443Internal medicine1.1660.9351.4550.174Other ward1.1250.7011.8050.626Other hospital1.1640.8961.5110.255Age1.0020.9971.0070.371APACHE II score1.0070.9891.0240.459SOFA score1.0070.9791.0350.651Sex (female as reference)1.0870.9101.2990.356AGI (AGI 1 as reference)AGI 2--30.4600.3530.599\< 0.001AGI 40.0560.0080.3980.004GCS score0.9450.9210.969\< 0.001*AGI* acute gastrointestinal injury, *APACHE II* Acute Physiology and Chronic Health Evaluation II, *GCS* Glasgow Coma Score, *HR* hazard ratio, *SOFA* Sequential Organ Failure Assessment

Factors associated with proportion of EN delivery {#Sec12}
-------------------------------------------------

In the multivariable linear regression model investigating factors associated with the EN proportion (Table [3](#Tab3){ref-type="table"}), greater SOFA scores (coefficient -- 0.002, 95% CI -- 0.008 to − 0.001; *p* = 0.024) and male gender (coefficient -- 0.144, 95% CI -- 0.203 to − 0.085; *p* \< 0.001) were found to be associated with lower EN proportion. As compared with AGI 1, AGI 2--3 was associated with lower EN proportion (coefficient -- 0.206, 95% CI -- 0.273 to − 0.139; *p* \< 0.001).Table 3Variables associated with proportion of EN on the study dayCoefficient2.5%97.5%*p* valueAge-- 0.002− 0.003− 0.0010.039APACHE II score0.004− 0.0010.0090.114SOFA score− 0.002− 0.008− 0.0010.024Sex (female as reference)− 0.144− 0.203− 0.0850.000Source of admission (emergency room as reference)Internal medicine0.036− 0.1010.1730.610Other hospital0.040− 0.0360.1160.307Surgery0.023− 0.0410.0880.478Ward− 0.026− 0.0940.0430.464EN start time (1-day increase)− 0.006− 0.006− 0.0120.001AGI (AGI 1 as reference)AGI 2--3− 0.206− 0.273− 0.1390.000AGI 4− 0.370− 1.2340.4950.401*AGI* acute gastrointestinal injury, *APACHE II* Acute Physiology and Chronic Health Evaluation II, *EN* enteral nutrition, *SOFA* Sequential Organ Failure Assessment

Discussion {#Sec13}
==========

This was the largest cross-sectional study in mainland China covering 118 ICUs in 116 hospitals. The study enrolled 1953 patients, including 1483 survivors and 312 nonsurvivors. The results showed that EN delivery was suboptimal in China, evidenced by only 32.7% of critically ill patients received EN feeding within 48 h after ICU admission. Only a minority of patients (17.8%) received 80% of the estimated energy target by EN within 7 days after ICU entry. In the multivariable analysis, AGI was independently associated with the initiation of EN, indicating that gastrointestinal dysfunction was the major obstacle prohibiting EN delivery. The severity of illness as reflected by the SOFA score was negatively associated with the EN proportion.

In a worldwide study involving 46 countries and 880 units, enteral feeding was prescribed to only 10% of patients on the first day but this number increased to more than 40% of patients after 5 days \[[@CR22]\]. In our study, 23.9% patients received EN on the first day and this percentage increased to 37% within 3 days. In another study conducted in Latin America, 59.7% of patients received \> 90% estimated daily target within 24 h after ICU admission \[[@CR23]\]. The study included parenteral nutrition, enteral nutrition or a combination, and thus the proportion was much higher than that in our study. The time to achieve \> 80% estimated energy target was longer in the present study as compared with other reports. For example, Yip et al. \[[@CR24]\] reported that the mean time to achieve \> 80% target was 1.8 days (SD 1.5 days). However, the proportion of patients receiving \> 80% energy target in the first 2 days was only 10.9% (50/459) in our study. Meanwhile, the median volume of EN in our study was 1000 exactly, suggesting that a more standard 1 L per 24 h is used and not related to target or body weight or BMI. This seems more cultural, nonprotocolized. According to the recent clinical practice guidelines \[[@CR25]\], EN should be initiated within 24--48 h for critically ill patients who are unable to maintain volitional intake. However, this target is far from being reached in most Chinese hospitals. A cohort study from China reported that the EN feeding protocol was able to increase the proportion of EN on day 2 (41.8 ± 22.3% vs 50.0 ± 28.3%; *p* = 0.006) \[[@CR13]\]. Thus, every effort should be made to standardize the EN feeding protocol to prompt EN delivery for critically ill patients.

Factors associated with EN initiation were investigated in the study. The results showed that patients with advanced AGI stage were less likely to receive EN, which was consistent with other reports. In a multicenter study, AGI grading was found to be associated with EN intolerance and the discontinuation of EN feeding \[[@CR26]\]. Although our study is cross-sectional in design and cannot deduce the causal relationship between AGI grade and EN discontinuation, we could propose that EN discontinuation might be attributable to the compromised gastrointestinal function. However, this practice may not be supported by empirical evidence, because there is evidence showing that advanced AGI grade should not be a contraindication of EN feeding. On the contrary, Jin et al. \[[@CR27]\] showed that the AGI grade was improved in the early EN group (*F*-statistic = 4.468; *p* \< 0.05), indicating that EN delivery for patients with moderate gastrointestinal impairment may help to accelerate the recovery of gastrointestinal function. Actually, any association between higher AGI and/or higher SOFA score and lower EN given indicates that increasing severity of disease is associated with decreasing EN tolerance as well as poorer outcome. It was counterintuitive to see that a greater value of GCS was statistically associated with reduced likelihood of EN initiation, but the clinical significance was marginal (HR 0.945, 95% CI 0.921--0.969; *p* \< 0.001). This could be explained by the fact that for patients with low GCS caused by trauma or stroke, we usually insert a GI tube on admission and start EN very early. After all, gastrointestinal dysfunction or shock, one of the major factors limiting EN use, is less common in stroke or traumatic brain injury patients.

In a linear regression model, we investigated factors associated with the proportion of the estimated energy requirement delivered via EN. The results showed that the SOFA score, gender and AGI were independently associated with the proportion. No wonder that a higher SOFA score is an obstacle of EN increments, as it is a measurement of organ dysfunction for critically ill patients and circulatory failure is an important component of the total score \[[@CR28]\]. The guidelines also suggest a delay of EN delivery in patients with circulatory failure \[[@CR25]\]. A novel finding in the study was that male patients were less likely to reach the estimated energy target as compared to females. Some may argue that this can be a false positive finding due to multiple testing. However, the effect size was large with male patients 26% lower in proportion than female patients (*p* \< 0.001). Such a large effect size cannot be simply explained by random errors \[[@CR29]\]. Probably, the physicians were more likely to give a fixed dose to patients without considering their body weight. Since men's body weight is usually greater than women's, they might receive a lower proportion of EN than female patients. In the linear model, AGI appeared to be an independent predictor of EN proportion. It is reasonable that physicians reduce the amount of EN in the presence of signs and symptoms that exaggerate the AGI grading \[[@CR30]\]. According to current guidelines, AGI was not a factor prohibiting the initiation of EN. For a patient with greater AGI, physicians can initiate but maybe not achieve the target so easily. Initiation has to do with protocols, awareness of the importance, preserving gut function and so on. Furthermore, the study showed that GI intolerance was a very uncommon reason to interrupt EN. Thus, the problem is not AGI but the culture of not starting EN.

Several limitations must be acknowledged. First, the study was a cross-sectional study that causal inference cannot be confirmed. For example, we could only conclude that there was an association between AGI and EN delivery, the causal relation cannot be well defined. While a high AGI score may prohibit physicians to add EN, it is also possible that EN delivery exacerbates the already compromised gastrointestinal function. Second, the study only recorded data on the study day and the EN delivery and gastrointestinal function before and after the study day remain unknown, which precluded the analysis of a temporal trend of the EN delivery. However, since we have a large number of patients, and the study day involved all consecutive days after ICU admission, this gives us an opportunity to investigate the current trend of EN delivery.

Conclusion {#Sec14}
==========

The study showed that EN delivery was suboptimal in Chinese ICUs, and that EN use in the early days after ICU admission should be paid more attention. One reason for this is that most Chinese hospitals lack a standardized EN feeding protocol for critically ill patients.

AGI

:   Acute gastrointestinal injury

APACHE II

:   Acute Physiology and Chronic Health Evaluation II

BG

:   Blood glucose

CI

:   Confidence interval

CRP

:   C-reactive protein

EN

:   Enteral nutrition

GCS

:   Glasgow Coma Score

GRV

:   Gastric residual volume

HR

:   Hazard ratio

ICU

:   Intensive care unit

IQR

:   Interquartile range

PEG/J

:   Percutaneous endoscopic gastrostomy/jejunostomy

SOFA

:   Sequential Organ Failure Assessment
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